trending Market Intelligence /marketintelligence/en/news-insights/trending/bbhvf7qwkkkkq_sccstqwa2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Atrium to sell biosurgery business to HJ Capital 1 in a strategic shift

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

Atrium to sell biosurgery business to HJ Capital 1 in a strategic shift

Atrium Medical Corp., a subsidiary of Getinge AB, will sell its biosurgery business to HJ Capital 1 in a strategic shift to focus on core therapeutic solutions.

Getinge acquired Atrium in 2011 for $680 million, adding the biosurgery arm to its business.

The biosurgery business develops solutions to reinforce soft tissue following injury and surgery. According to Atrium, 2017 the sales of the biosurgery business were about 128 million Swedish kronor.

All assets and liabilities of the biosurgery business will be transferred to HJ Capital 1, excluding surgical mesh product liability claims against Atrium Medical for products sold before the closing of the deal and related insurance claims.

Financial terms of the deal were not disclosed.

HJ Capital 1 operates SeCQure Surgical, which produces medical devices used in general surgical processes.